Skip to content
Triangle logo TriangleGet started
← Childhood Acute Myeloid Leukemia

HEALTH PROFESSIONAL · SOURCE READING

Chemotherapy with HSCT

Source: Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Recurrent or Refractory Childhood AML / Refractory Childhood AML (Induction Failure) / Treatment of refractory AML

Like patients with relapsed AML, patients with induction failure are typically directed toward HSCT once they attain a remission. Studies suggest a better EFS rate in patients treated with HSCT than in patients treated with chemotherapy only (31.2% vs. 5%; P < .0001). Attainment of morphological CR for these patients is a significant prognostic factor for disease-free survival (DFS) after HSCT (46% vs. 0%; P = .02). Failure primarily resulted from relapse (relapse risk, 53.9% vs. 88.9%; P = .02).[54]

Source links and citations

For more information about chemotherapy to induce remission, see the Chemotherapy section in the Treatment of Recurrent AML section.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice